bireociclib + clarithromycin

This is a combination of bireociclib (XZP-3287), an orally bioavailable selective inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6) with potential antineoplastic activity, and clarithromycin, a macrolide antibiotic. Bireociclib works by inhibiting CDK4/6, which are key regulators of cell cycle progression. Clarithromycin is a potent CYP3A4 inhibitor, which may affect the metabolism of bireociclib. This combination is likely being studied for potential drug interactions, as CDK4/6 inhibitors are typically metabolized by CYP3A4 enzymes, and clarithromycin could potentially increase bireociclib exposure.

Other names

birociclib + clarithromycin